Agile Therapeutics Stock Price, News & Analysis (NASDAQ:AGRX)

$3.65 -0.02 (-0.54 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$3.65
Today's Range$3.55 - $3.75
52-Week Range$1.93 - $5.60
Volume45,406 shs
Average Volume124,894 shs
Market Capitalization$124.78 million
P/E Ratio-3.97
Dividend YieldN/A
Beta2.16

About Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics logoAgile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

Receive AGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGRX
CUSIPN/A
Phone609-683-1880

Debt

Debt-to-Equity Ratio0.14%
Current Ratio4.10%
Quick Ratio4.10%

Price-To-Earnings

Trailing P/E Ratio-3.96734818099803
Forward P/E Ratio-3.76
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.47 per share
Price / Book2.48

Profitability

Trailing EPS($0.92)
Net Income$-28,740,000.00
Net MarginsN/A
Return on Equity-81.68%
Return on Assets-53.67%

Miscellaneous

Employees19
Outstanding Shares34,190,000

Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics Inc (NASDAQ:AGRX) posted its quarterly earnings data on Monday, November, 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.03. View Agile Therapeutics' Earnings History.

Where is Agile Therapeutics' stock going? Where will Agile Therapeutics' stock price be in 2018?

7 analysts have issued 12 month price targets for Agile Therapeutics' shares. Their forecasts range from $5.00 to $13.00. On average, they anticipate Agile Therapeutics' share price to reach $9.20 in the next year. View Analyst Ratings for Agile Therapeutics.

What are Wall Street analysts saying about Agile Therapeutics stock?

Here are some recent quotes from research analysts about Agile Therapeutics stock:

  • 1. HC Wainwright analysts commented, "it as Just Another Delay; Reiterate Buy but Lower to $8 Stock Data 12/21/2017 Price $4.76 Exchange NASDAQ Price Target $8.00 52-Week High $6.62 52-Week Low $2.04 Enterprise Value (M) $131.3 Market Cap (M) $163 Shares Outstanding (M) 34.2 3 Month Avg Volume 267,948 Short Interest (M) 0.30 Balance Sheet Metrics Cash (M) $43.8 Total Debt (M) $12.1 Total Cash/Share $1.28 EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.27) (0.26)A (0.28) 2Q (0.29) (0.26)A (0.26) 3Q (0.27) (0.22)A (0.29) 4Q (0.18) (0.24) (0.32) FY (1.02) (0.98) (1.16) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 0.0 0.0A 0.0 2Q 0.0 0.0A 0.0 3Q 0.0 0.0A 0.0 4Q 0.0 0.0 0.0 FY 0.0 0.0 0.0 7 6 5 4 3 2 1 DEC- 16 APR- 17 AUG- 17 DEC- 17 20 15 10 5 0 Vol. (mil) Price Twirla Complete Response Letter surprisingly focused on patch adhesion; we believe the issues are readily addressable. The consensus investor Twirla sticking issue has been around the “high” Phase 3 Pearl Index (implied lower efficacy) vs. prior." (12/22/2017)
  • 2. Cantor Fitzgerald analysts commented, "One time when you’re happy to receive a belated Christmas present. The PDUFA date for Twirla is December 26, and we believe it reasonable that an approval will occur around then. We suppose it might be possible that FDA staffers clear their plates before the holiday season. AGRX management has deftly avoided addressing whether labeling discussions have occurred as that would be an indication that FDA approval could be forthcoming." (11/6/2017)

Who are some of Agile Therapeutics' key competitors?

Who are Agile Therapeutics' key executives?

Agile Therapeutics' management team includes the folowing people:

  • Alfred Altomari, Chairman of the Board, President, Chief Executive Officer (Age 57)
  • Scott M. Coiante, Chief Financial Officer, Vice President (Age 48)
  • Elizabeth Garner M.D., Senior Vice President, Chief Medical Officer (Age 47)
  • Renee Selman, Chief Commercial Officer
  • Abhijeet J. Lele, Lead Independent Director (Age 49)
  • John W. Hubbard Ph.D., Director (Age 60)
  • Ajit S. Shetty Ph.D., Director
  • James Patrick Tursi M.D., Director (Age 51)
  • Seth H. Z. Fischer, Independent Director (Age 61)

Who owns Agile Therapeutics stock?

Agile Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (9.89%), Franklin Resources Inc. (8.39%), Aisling Capital LLC (3.82%), Needham Investment Management LLC (1.20%), Renaissance Technologies LLC (1.07%) and Broadfin Capital LLC (1.05%). Company insiders that own Agile Therapeutics stock include Alfred Altomari and Renee Selman. View Institutional Ownership Trends for Agile Therapeutics.

Who sold Agile Therapeutics stock? Who is selling Agile Therapeutics stock?

Agile Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Aisling Capital LLC, Millennium Management LLC, Needham Investment Management LLC and Falcon Point Capital LLC. View Insider Buying and Selling for Agile Therapeutics.

Who bought Agile Therapeutics stock? Who is buying Agile Therapeutics stock?

Agile Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Broadfin Capital LLC, Renaissance Technologies LLC, Franklin Resources Inc. and Bank of New York Mellon Corp. Company insiders that have bought Agile Therapeutics stock in the last two years include Alfred Altomari and Renee Selman. View Insider Buying and Selling for Agile Therapeutics.

How do I buy Agile Therapeutics stock?

Shares of Agile Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agile Therapeutics' stock price today?

One share of Agile Therapeutics stock can currently be purchased for approximately $3.65.

How big of a company is Agile Therapeutics?

Agile Therapeutics has a market capitalization of $124.78 million. The specialty pharmaceutical company earns $-28,740,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. Agile Therapeutics employs 19 workers across the globe.

How can I contact Agile Therapeutics?

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]


MarketBeat Community Rating for Agile Therapeutics (AGRX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  228 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Agile Therapeutics (NASDAQ:AGRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.713.003.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.20$9.20$10.20$10.00
Price Target Upside: 233.33% upside233.33% upside110.31% upside200.30% upside

Agile Therapeutics (NASDAQ:AGRX) Consensus Price Target History

Price Target History for Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics (NASDAQ:AGRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/28/2017HC WainwrightSet Price TargetBuy$8.00LowView Rating Details
12/28/2017Noble FinancialReiterated RatingBuyLowView Rating Details
12/28/2017Janney Montgomery ScottDowngradeBuy -> NeutralLowView Rating Details
12/26/2017William BlairDowngradeOutperform -> Market PerformHighView Rating Details
12/22/2017Cantor FitzgeraldReiterated RatingBuy$5.00HighView Rating Details
10/18/2017Royal Bank of CanadaReiterated RatingBuy$10.00N/AView Rating Details
3/11/2017FBR & CoSet Price TargetBuy$10.00LowView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Agile Therapeutics (NASDAQ:AGRX) Earnings History and Estimates Chart

Earnings by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics (NASDAQ AGRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.25)($0.22)ViewN/AView Earnings Details
7/28/2017Q2 2017($0.28)($0.26)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.31)($0.26)ViewN/AView Earnings Details
3/8/2017Q4 2016($0.28)($0.29)ViewN/AView Earnings Details
11/7/2016Q3($0.35)($0.27)ViewN/AView Earnings Details
8/8/2016Q2($0.29)($0.29)ViewN/AView Earnings Details
5/9/2016Q1($0.38)($0.27)ViewN/AView Earnings Details
3/9/2016Q4 2015($0.43)($0.17)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.42)($0.42)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.37)($0.38)ViewN/AView Earnings Details
5/12/2015Q1 2015($0.35)($0.35)ViewN/AView Earnings Details
3/26/2015Q4 2014($0.40)($0.37)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.50)($0.34)ViewN/AView Earnings Details
8/14/2014Q2 2014($0.43)($0.46)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Agile Therapeutics (NASDAQ:AGRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.97 EPS
Next Year EPS Consensus Estimate: $-0.82 EPS

Dividends

Dividend History for Agile Therapeutics (NASDAQ:AGRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Agile Therapeutics (NASDAQ AGRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 68.26%
Insider Trades by Quarter for Agile Therapeutics (NASDAQ:AGRX)
Insider Trades by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics (NASDAQ AGRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2017Alfred AltomariChairmanBuy10,000$3.34$33,400.00161,587View SEC Filing  
8/25/2017Renee SelmanInsiderBuy7,250$3.35$24,287.5060,583View SEC Filing  
5/11/2017Alfred AltomariChairmanBuy10,000$3.51$35,100.00151,587View SEC Filing  
5/11/2017Renee SelmanInsiderBuy53,333$3.68$196,265.4453,333View SEC Filing  
1/27/2016Jay MoorinMajor ShareholderBuy393,700$6.35$2,499,995.00View SEC Filing  
6/2/2015Alfred AltomariCEOBuy2,500$8.73$21,825.00View SEC Filing  
1/23/2015Jay MoorinMajor ShareholderBuy811,966$5.85$4,750,001.10View SEC Filing  
5/29/2014Care Capital Iii LlcMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
5/23/2014Andrew N SchiffDirectorBuy1,333,333$6.00$7,999,998.00View SEC Filing  
5/22/2014Ab InvestorMajor ShareholderBuy1,000,000$6.00$6,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Agile Therapeutics (NASDAQ AGRX) News Headlines

Source:
DateHeadline
Agile Therapeutics Inc (AGRX) Given Average Recommendation of "Buy" by BrokeragesAgile Therapeutics Inc (AGRX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 3 at 5:28 AM
New Research Coverage Highlights Oracle, General Dynamics, Agile Therapeutics, Fidelity Southern, Syros Pharmaceuticals, and MSA Safety Incorporated — Consolidated Revenues, Company Growth, and Expectations for 2018New Research Coverage Highlights Oracle, General Dynamics, Agile Therapeutics, Fidelity Southern, Syros Pharmaceuticals, and MSA Safety Incorporated — Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - January 24 at 8:06 AM
Technical Perspectives on Generic Drugs Stocks -- Fibrocell Science, Galectin Therapeutics, Agile Therapeutics, and ... - PR Newswire (press release)Technical Perspectives on Generic Drugs Stocks -- Fibrocell Science, Galectin Therapeutics, Agile Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - January 20 at 7:25 AM
Agile Therapeutics Inc (AGRX) Receives Average Recommendation of "Buy" from AnalystsAgile Therapeutics Inc (AGRX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 7:58 AM
Zacks: Brokerages Anticipate Agile Therapeutics Inc (AGRX) to Announce -$0.24 EPSZacks: Brokerages Anticipate Agile Therapeutics Inc (AGRX) to Announce -$0.24 EPS
www.americanbankingnews.com - January 4 at 7:28 PM
Agile Therapeutics (AGRX) Rating Reiterated by Noble FinancialAgile Therapeutics (AGRX) Rating Reiterated by Noble Financial
www.americanbankingnews.com - December 29 at 5:04 PM
Agile Therapeutics (AGRX) Stock Rating Lowered by Janney Montgomery ScottAgile Therapeutics (AGRX) Stock Rating Lowered by Janney Montgomery Scott
www.americanbankingnews.com - December 29 at 5:04 PM
HC Wainwright Analysts Give Agile Therapeutics (AGRX) a $8.00 Price TargetHC Wainwright Analysts Give Agile Therapeutics (AGRX) a $8.00 Price Target
www.americanbankingnews.com - December 29 at 3:34 PM
FY2017 EPS Estimates for Agile Therapeutics Inc (AGRX) Decreased by Cantor FitzgeraldFY2017 EPS Estimates for Agile Therapeutics Inc (AGRX) Decreased by Cantor Fitzgerald
www.americanbankingnews.com - December 29 at 7:56 AM
Agile Therapeutics: Sell-Off Post CRL Makes It Worth A Look - Seeking AlphaAgile Therapeutics: Sell-Off Post CRL Makes It Worth A Look - Seeking Alpha
seekingalpha.com - December 27 at 9:58 AM
Critical Contrast: Relypsa (RLYP) and Agile Therapeutics (AGRX)Critical Contrast: Relypsa (RLYP) and Agile Therapeutics (AGRX)
www.americanbankingnews.com - December 26 at 8:01 PM
Agile Therapeutics (AGRX) Downgraded to Market Perform at William BlairAgile Therapeutics (AGRX) Downgraded to Market Perform at William Blair
www.americanbankingnews.com - December 26 at 7:36 AM
Agile Therapeutics (AGRX) "Buy" Rating Reaffirmed at Cantor FitzgeraldAgile Therapeutics' (AGRX) "Buy" Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - December 25 at 1:32 PM
Agile Therapeutics (AGRX) Stock Rating Reaffirmed by Noble FinancialAgile Therapeutics (AGRX) Stock Rating Reaffirmed by Noble Financial
www.americanbankingnews.com - December 25 at 12:38 PM
Agile Therapeutics plunges toward record low after FDA rejects contraceptive patchs NDA - MarketWatchAgile Therapeutics plunges toward record low after FDA rejects contraceptive patch's NDA - MarketWatch
www.marketwatch.com - December 23 at 3:46 PM
Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention ... - GlobeNewswire (press release)Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention ... - GlobeNewswire (press release)
globenewswire.com - December 23 at 3:46 PM
Agile Therapeutics (AGRX) Receives CRL from FDA for Twirla for Prevention of PregnancyAgile Therapeutics (AGRX) Receives CRL from FDA for Twirla for Prevention of Pregnancy
www.streetinsider.com - December 22 at 8:42 PM
Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of PregnancyAgile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy
finance.yahoo.com - December 22 at 8:42 PM
Agile Therapeutics plunges toward record low after FDA rejects contraceptive patchs NDAAgile Therapeutics plunges toward record low after FDA rejects contraceptive patch's NDA
finance.yahoo.com - December 22 at 8:42 PM
Agile Therapeutics (AGRX) PT Set at $8.00 by HC WainwrightAgile Therapeutics (AGRX) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - December 22 at 3:58 PM
Mid-Day Market Update: Ignyta Surges Following Merger Deal With Roche; Agile Therapeutics Shares Plunge - NasdaqMid-Day Market Update: Ignyta Surges Following Merger Deal With Roche; Agile Therapeutics Shares Plunge - Nasdaq
www.nasdaq.com - December 22 at 3:40 PM
Agile Therapeutics (AGRX) Receives CRL from FDA for Twirla for Prevention of Pregnancy - StreetInsider.comAgile Therapeutics (AGRX) Receives CRL from FDA for Twirla for Prevention of Pregnancy - StreetInsider.com
www.streetinsider.com - December 22 at 3:40 PM
Who Are The Largest Shareholders In Agile Therapeutics Inc (NASDAQ:AGRX)?Who Are The Largest Shareholders In Agile Therapeutics Inc (NASDAQ:AGRX)?
finance.yahoo.com - December 21 at 3:24 PM
Agile Therapeutics, Inc. (AGRX) Receives Average Rating of "Buy" from AnalystsAgile Therapeutics, Inc. (AGRX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 15 at 5:52 AM
Head to Head Survey: Agile Therapeutics (AGRX) vs. Celsion (CLSN)Head to Head Survey: Agile Therapeutics (AGRX) vs. Celsion (CLSN)
www.americanbankingnews.com - December 13 at 5:12 AM
Is It Too Late To Buy Agile Therapeutics Inc (AGRX)?Is It Too Late To Buy Agile Therapeutics Inc (AGRX)?
finance.yahoo.com - December 1 at 3:24 PM
Agile Therapeutics, Inc. (AGRX) Stock Rating Reaffirmed by Cantor FitzgeraldAgile Therapeutics, Inc. (AGRX) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - November 20 at 6:46 PM
Agile Therapeutics, Inc. (AGRX) Given Consensus Rating of "Buy" by AnalystsAgile Therapeutics, Inc. (AGRX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - November 20 at 5:38 AM
Corium Q4 Sales Top Expectations Ahead Of Slew Of Near-Term Catalysts - BenzingaCorium Q4 Sales Top Expectations Ahead Of Slew Of Near-Term Catalysts - Benzinga
www.benzinga.com - November 17 at 3:21 PM
Corium Q4 Sales Top Expectations Ahead Of Slew Of Near-Term CatalystsCorium Q4 Sales Top Expectations Ahead Of Slew Of Near-Term Catalysts
www.msn.com - November 17 at 10:58 AM
Agile Therapeutics (AGRX) PT Raised to $41 at Wedbush - StreetInsider.comAgile Therapeutics (AGRX) PT Raised to $41 at Wedbush - StreetInsider.com
www.streetinsider.com - November 16 at 10:52 AM
What Investors Should Know About Agile Therapeutics Inc’s (AGRX) Financial StrengthWhat Investors Should Know About Agile Therapeutics Inc’s (AGRX) Financial Strength
finance.yahoo.com - November 16 at 10:52 AM
-$0.26 EPS Expected for Agile Therapeutics, Inc. (AGRX) This Quarter-$0.26 EPS Expected for Agile Therapeutics, Inc. (AGRX) This Quarter
www.americanbankingnews.com - November 12 at 5:42 PM
FY2017 EPS Estimates for Agile Therapeutics, Inc. Lowered by Cantor Fitzgerald (AGRX)FY2017 EPS Estimates for Agile Therapeutics, Inc. Lowered by Cantor Fitzgerald (AGRX)
www.americanbankingnews.com - November 10 at 8:36 AM
Agile Therapeutics, Inc. Forecasted to Post FY2017 Earnings of ($0.97) Per Share (AGRX)Agile Therapeutics, Inc. Forecasted to Post FY2017 Earnings of ($0.97) Per Share (AGRX)
www.americanbankingnews.com - November 10 at 8:34 AM
Agile Therapeutics, Inc. (AGRX) to Post FY2017 Earnings of ($0.96) Per Share, William Blair ForecastsAgile Therapeutics, Inc. (AGRX) to Post FY2017 Earnings of ($0.96) Per Share, William Blair Forecasts
www.americanbankingnews.com - November 9 at 8:44 AM
William Blair Weighs in on Agile Therapeutics, Inc.s FY2019 Earnings (AGRX)William Blair Weighs in on Agile Therapeutics, Inc.'s FY2019 Earnings (AGRX)
www.americanbankingnews.com - November 8 at 9:52 PM
AGRX: Countdown to Dec. 26, 2017 PDUFA for Twirla®AGRX: Countdown to Dec. 26, 2017 PDUFA for Twirla®
finance.yahoo.com - November 8 at 5:50 PM
Agile Therapeutics, Inc. (AGRX) Releases Quarterly  Earnings Results, Beats Estimates By $0.03 EPSAgile Therapeutics, Inc. (AGRX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - November 7 at 11:15 AM
Cantor Fitzgerald Reiterates "Buy" Rating for Agile Therapeutics, Inc. (AGRX)Cantor Fitzgerald Reiterates "Buy" Rating for Agile Therapeutics, Inc. (AGRX)
www.americanbankingnews.com - November 7 at 12:16 AM
Agile Therapeutics reports 3Q lossAgile Therapeutics reports 3Q loss
finance.yahoo.com - November 6 at 9:26 PM
Agile Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Agile Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 6 at 4:26 PM
Agile Therapeutics Reports Third Quarter 2017 Financial ResultsAgile Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 6 at 4:26 PM
Agile Therapeutics Reports Third Quarter 2017 Financial ResultsAgile Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 6 at 4:26 PM
Form 8-K AGILE THERAPEUTICS INC For: Oct 31 - StreetInsider.com - StreetInsider.comForm 8-K AGILE THERAPEUTICS INC For: Oct 31 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - November 4 at 5:08 PM
Agile Therapeutics (AGRX) Announces Additional Phase 3 SECURE Trial Results for TwirlaAgile Therapeutics (AGRX) Announces Additional Phase 3 SECURE Trial Results for Twirla
www.streetinsider.com - October 31 at 9:56 PM
Agile Therapeutics (AGRX) Announces Additional Phase 3 SECURE Trial Results for Twirla - StreetInsider.comAgile Therapeutics (AGRX) Announces Additional Phase 3 SECURE Trial Results for Twirla - StreetInsider.com
www.streetinsider.com - October 31 at 4:52 PM
Agile Therapeutics (AGRX) Announces Additional Phase 3 SECURE Trial Results for Twirla - StreetInsider.comAgile Therapeutics (AGRX) Announces Additional Phase 3 SECURE Trial Results for Twirla - StreetInsider.com
www.streetinsider.com - October 31 at 4:52 PM
Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2017Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2017
finance.yahoo.com - October 31 at 4:52 PM
Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2017Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2017
finance.yahoo.com - October 31 at 4:52 PM

SEC Filings

Agile Therapeutics (NASDAQ:AGRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Agile Therapeutics (NASDAQ:AGRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Agile Therapeutics (NASDAQ AGRX) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.